Intralesional and perilesional application of an epidermal growth factor (Heberprot-P®) in diabetic foot ulcers. Part one

Jose Fernandez Montequin; Llipsy Santiesteban Bonachea; Jorge Berlanga Acosta; C V Peres; W S Gutierres; G A Duarte

Intralesional and perilesional application of an epidermal growth factor (Heberprot-P®) in diabetic foot ulcers. Part one

Angiol Sosud Khir. 2018;24(4):33-42.

[Article in English, Russian]

Authors

Jose Fernandez Montequin¹, Llipsy Santiesteban Bonachea², Jorge Berlanga Acosta³, C V Peres¹, W S Gutierres¹, G A Duarte¹

Affiliations

¹ National Institute of Angiology and Vascular Surgery, Havana, Cuba.
² Medical University of Havana, Havana, Cuba.
³ Center for Genetic Engineering and Biotechnology, Havana, Cuba.

PMID: 30531767

Abstract

For 15 years, from 2001, we began to apply Heberprot-P®, an injectable Epidermal Growth Factor (0.75 μg) created in the Center of Biotechnology, in Havana, Cuba. More than 159,000 patients were treated around the world, from 25 countries, with, with only 9-11% high-level amputations. In this paper, we discuss our experience in the treatment of the most complex diabetic foot ulcers cases for the last 15 years.

MeSH terms

Administration, Topical
Anti-Ulcer Agents / administration & dosage
Anti-Ulcer Agents / adverse effects
Cuba
Diabetic Foot* / diagnosis
Diabetic Foot* / therapy
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Monitoring / methods
Epidermal Growth Factor* / administration & dosage
Epidermal Growth Factor* / adverse effects
Humans
Injections, Intralesional
Recombinant Proteins
Treatment Outcome
Wound Healing / drug effects*

Substances

Anti-Ulcer Agents
Recombinant Proteins
Epidermal Growth Factor